Cholesterol Screening Starts at 19 Now: 2026 ACC/AHA Guideline Overhaul

The American College of Cardiology and American Heart Association released a sweeping update to cholesterol care on March 13, 2026. The new guideline replaces the 2018 recommendations and introduces earlier screening ages, a modern risk calculator, universal Lp(a) testing, and lower LDL-cholesterol treatment targets for patients with established cardiovascular disease (JACC, 2026).

Key Takeaways

• Lipid screening is now recommended beginning at age 19, with cholesterol screening for all children ages 9 to 11 not previously screened (ACC, 2026).
• The PREVENT-ASCVD equations replace the Pooled Cohort Equations for adults ages 30 to 79 for primary prevention (JACC, 2026).
• Universal Lp(a) testing at least once in adulthood is now recommended because high Lp(a) carries independent cardiovascular risk (ACC, 2026).

What Changed From the 2018 Guideline?

The 2026 document is retitled from "Management of Blood Cholesterol" to "Management of Dyslipidemia" to reflect broader attention to triglycerides, remnant particles, and Lp(a) beyond LDL alone. It restores LDL-cholesterol treatment goals, introduces the PREVENT risk calculator, and recommends earlier lifestyle and pharmacotherapy intervention (JACC, 2026).

Citation capsule: The 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia was developed with 11 co-signing medical associations and replaces the 2018 Guideline on the Management of Blood Cholesterol, marking the most comprehensive update in eight years (JACC, 2026).

What Is PREVENT-ASCVD?

PREVENT-ASCVD is a contemporary cardiovascular risk calculator designed for adults ages 30 to 79 without known atherosclerotic cardiovascular disease or subclinical atherosclerosis. It estimates 10- and 30-year risk of heart attack and stroke using cholesterol, blood pressure, age, health habits, and risk enhancers such as family history, inflammatory conditions, and reproductive risk markers (ACC, 2026).

Citation capsule: The ACC notes that PREVENT-ASCVD allows clinicians to personalize risk scoring by incorporating risk enhancers such as preeclampsia, gestational diabetes, and high-risk ancestry, which older calculators did not include (ACC, 2026).

When Should You Start Medication?

For primary prevention, the guideline recommends considering lipid-lowering therapy in adults with a 10-year PREVENT-ASCVD risk of 5% or greater, and initiating therapy when risk reaches 7.5% or greater. For patients with established cardiovascular disease, the goal is intensive LDL-C lowering to less than 55 mg/dL using high-intensity statins plus ezetimibe and, if needed, PCSK9 inhibitors or inclisiran (JACC, 2026).

What Is Lp(a), and Why Does It Matter?

Lipoprotein(a) is a genetically determined particle that raises heart attack and stroke risk independent of LDL cholesterol. An Lp(a) of 125 nmol/L or greater is associated with about 1.4-fold increased long-term risk; at 250 nmol/L, the risk doubles. Lifestyle changes have minimal effect on Lp(a), so once you know your level, it does not need frequent rechecking (JACC, 2026).

Citation capsule: The 2026 guideline recommends measuring Lp(a) at least once in adulthood because high levels are largely genetically determined and associated with roughly two-fold increased long-term risk of heart attack or stroke at higher thresholds (JACC, 2026).

What About Coronary Artery Calcium Scoring?

For men age 40 and older and women age 45 and older with borderline or intermediate 10-year risk, selective coronary artery calcium scoring can help decide whether to start a statin. Any detectable calcium supports an LDL-C goal of less than 100 mg/dL, with lower targets as calcium burden increases (JACC, 2026).

Frequently Asked Questions

Do I need a statin if my cholesterol is normal?

Possibly. The decision now uses PREVENT-ASCVD risk, not LDL alone. A normal total cholesterol does not rule out higher risk if other factors are present (JACC, 2026).

Should my teenager get cholesterol tested?

The guideline recommends universal cholesterol screening for children ages 9 to 11 if not previously screened, and earlier testing for children with a family history of premature cardiovascular disease (ACC, 2026).

What if my Lp(a) is high?

High Lp(a) does not change with diet or exercise. Treatment typically focuses on lowering LDL-C aggressively to offset the added risk. PCSK9 inhibitors and aspirin decisions should be individualized with your clinician (JACC, 2026).

Does this change my current statin dose?

If you already have cardiovascular disease, the new guideline reinforces intensive LDL-C lowering to below 55 mg/dL. If you are in primary prevention, your target depends on your PREVENT-ASCVD score and risk enhancers (JACC, 2026).

Conclusion

The 2026 dyslipidemia guideline shifts cholesterol care from reaction to prevention. Earlier screening, modern risk calculation, and lower LDL-C targets aim to stop atherosclerosis before the first heart attack or stroke. If you have not had your lipids checked recently, or if you are unsure whether your risk has been estimated with a contemporary calculator, this is the year to ask.